ClinicalTrials.gg
Not yet recruitingNCT07779603Updated Aug 21, 2026

The Relationship Between Lipedema and Osteoporosis

An observational study in Lipedema and Osteoporosis, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the relationship between lipedema and osteoporosis and to examine factors that may be associated with osteoporosis in individuals with lipedema.

Read the detailed description

Clinical characteristics such as age, body mass index (BMI), education level, marital status, age at menopause, number of births, duration of illness, occupation, duration of lactation, history of fractures, family history of fractures, smoking, alcohol consumption, dairy product intake, sun exposure habits, stage of lipedema, and type of lipedema will be recorded. Your blood test results obtained prior to routine osteoporosis treatment (complete blood count, erythrocyte sedimentation rate, C-reactive protein, calcium, phosphorus, alkaline phosphatase (ALP), parathyroid hormone (PTH), and 25-hydroxyvitamin D levels) will be recorded. The severity of lower extremity pain will be assessed using the Visual Analog Scale (VAS). Scores on the lower extremity functional scale will be recorded. For patients with lipedema, the average and most severe lower extremity pain experienced over the past month will be recorded. Dual-energy X-ray absorptiometry (DEXA) measurements assessing current bone loss will be recorded for the lumbar and hip regions.

02

Conditions studied

  • Lipedema
  • Osteoporosis
03

In context

Lipedema

85 studies on the registry are indexed under Lipedema; 32 are open to participants now.

This study's planned enrollment of 120 is above the median of 90 across 42 observational studies indexed under Lipedema.

Browse Lipedema studies →

Lead sponsor

Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 120 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

postmenopausal patients with or without a diagnosis of lipedema

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • being literate
  • voluntarily agreeing to participate in the study
  • being a woman
  • having a diagnosis of lipedema

Exclusion criteria

Exclusion Criteria:

  • the presence of other types of edema in which a component other than lipedema predominates (e.g., lymphedema, venous edema, edema associated with heart or kidney failure, etc.)
  • chronic liver disease,
  • (BMI) of over 50.0 (this condition reflects severe obesity, which has a significant impact on health beyond lipedema alone)
  • the presence of rheumatological diseases that may lead to secondary osteoporosis
  • a history of cancer, endocrine disorders, neurological disorders, certain gastrointestinal disorders
  • use of medications related to osteoporosis
  • being under 18 years of age
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Group1

    postmenopausal patients diagnosed with lipedema

    Other: DXA

  • Group2

    postmenopausal patients without lipedema

    Other: DXA

Interventions

  • OtherDXA

    Dual-energy X-ray absorptiometry (DXA) measurements will be recorded for the lumbar and hip regions

06

What researchers measure

Primary outcomes

  1. DXA

    Dual-energy X-ray absorptiometry (DEXA) measurements for the lumbar and hip regions for the lumbar and hip regions

    Time frame: 1 day

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07779603
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Aug 20, 2026 (estimated)
Primary completion
Sep 16, 2026 (estimated)
Completion
Sep 16, 2026 (estimated)
Last update
Aug 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion